GX-19
GX-19 is a DNA vaccine candidate for the prevention of COVID-19. It is developed by Genexine, a South Korean biotechnology company. The vaccine candidate is currently in the clinical trial phase.
Overview
GX-19 is a DNA-based vaccine that uses a plasmid, a small, circular piece of DNA, to deliver a piece of the SARS-CoV-2 virus's genetic code into cells. This genetic code is for the virus's spike protein, which it uses to enter human cells. Once inside the cells, the genetic code instructs them to produce the spike protein. This, in turn, triggers an immune response, which includes the production of antibodies that can recognize and neutralize the spike protein if the person is later exposed to the actual virus.
Development and Clinical Trials
The development of GX-19 began in early 2020, shortly after the genetic sequence of SARS-CoV-2 was made publicly available. Genexine used its proprietary HyFc platform to design the vaccine.
The first phase of clinical trials for GX-19 began in June 2020. This phase involved testing the vaccine on a small group of healthy volunteers to assess its safety and to determine the appropriate dosage. The results of this phase were promising, with no serious adverse events reported and participants developing antibodies against SARS-CoV-2.
The second phase of clinical trials began in December 2020. This phase is larger and involves testing the vaccine on a more diverse group of participants to further assess its safety and efficacy.
Potential Advantages
One potential advantage of GX-19 is that, as a DNA vaccine, it does not require the same cold storage conditions as some other types of COVID-19 vaccines. This could make it easier to distribute, particularly in regions with limited cold storage infrastructure.
Another potential advantage is that DNA vaccines can be designed and produced relatively quickly, which could be beneficial in responding to new variants of SARS-CoV-2.
See Also
References
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD